June 17, 2021 at 4:15 am #9278KindaCannaParticipant
The time period of 2005-2010 was the inception of the CBD industry, as it is known today. This period of time in CBD research was when researchers began to become more enlightened as to the potential of CBD, THC and of other cannabinoids. The CBD industry was still mostly known and studied in terms of medical cannabis, until the next decade. But entrepreneurs and cannabis scholars worked harder at lending a scientific perspective to this rising interest in CBD and other cannabinoids. The reward and result were that more was learned about CBD between 2005 and 2010 than in any previous five year time period.
Augmenting prior research, there was a review in 2006 of available evidence that was sought out to more fully discern the antipsychotic and anti- schizophrenia potential of CBD. Cannabidiol appears to lessen the action of THC to induce psychosis. This effect was seen both in animal studies, and in clinical studies involving psychosis induced by ketamine.
Case studies of schizophrenic patients were conducted in which the patients were given CBD. In addition, a preliminary study of a controlled trial comparing CBD with an atypical antipsychotic medication, have shown that CBD can be a safe and well tolerated treatment for schizophrenia. Future studies on the use of CBD in other psychotic conditions, in addition to schizophrenia, in which CBD is used comparatively with traditional, atypical antipsychotic medication, are indicated.June 18, 2021 at 4:34 am #9282DanielleModerator
Building upon earlier research in the area of how cannabidiol can alleviate psychotic symptoms in schizophrenia, researchers in another study focused on identifying specific pathways in the brain, on how this is achieved. The scientists wished to identify the exact mechanisms which are responsible for the impact of CBD on certain types of psychosis, as are exhibited in schizophrenia. The result was that the researchers concluded that CBD regulated concentrations of a neurochemical called anandamide. This is an important neurotransmitter that promotes feelings of bliss or happiness. Therefore, in addition to the study of how this chemical impacts the treatment of schizophrenia, researchers are also interested in how the relationship between CBD and anandamide may be important in other areas of psychology, as well.
Anandamide is an endocannabinoid for which cannabidiol can inhibit the rate at which it is broken down, or degraded. Even though cannabidiol is a component of the cannabis plant which does not activate cannabinoid receptors, CBD at increased levels in the brain and in spinal fluid can increase the levels of anandamide, and decrease psychotic symptoms. This mechanism of enhanced signaling of anandamide leads to a lower rate of transition, or to a delayed transition, from symptoms occurring before a more severe psychotic episode.
The approach taken to show how anandamide delayed the more severe symptoms of psychosis was performed in a double-blind, randomized clinical trial of CBD, as compared with a potent antipsychotic agent, called amisulpride. These were administered during acute psychotic episodes to evaluate the clinical relevance to the researchers’ initial findings. Both treatments, with amisulpride and CBD, were found to be safe, and led to marked improvement. Cannabidiol displayed a noticeably superior profile regarding side effects. The treatment with the CBD also elevated the levels of serum anandamide in the brain, and this effect led to significant clinical improvement of symptoms. Overall, the method by which the anandamide is prevented from being broken down by the CBD may contribute to its antipsychotic properties. This is a new mechanism by which to treat schizophrenia.
- You must be logged in to reply to this topic.